Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Endogenous Secretory Receptor for Advanced Glycation Endproducts Levels Are Correlated With Serum Pentosidine and CML in Patients With Type 1 Diabetes

Endogenous Secretory Receptor for Advanced Glycation Endproducts Levels Are Correlated With Serum... Letter to the Editor Endogenous Secretory Receptor for Advanced Glycation Endproducts Levels Are Correlated With Serum Pentosidine and CML in Patients With Type 1 Diabetes Junnosuke Miura, Yasuhiko Yamamoto, Mari Osawa, Takuo Watanabe, Hideto Yonekura, Yasuko Uchigata, Hiroshi Yamamoto, Yasuhiko Iwamoto dvanced glycation end products (AGEs) and receptor therapy and insulin dose was 0.830.31 U/kgBw. These for AGE (RAGE)-mediated mechanism has been patients included: normoalbuminuria [albumin creatinine ra- Aimplicated in the pathogenesis of the vascular de- tio (ACR) 30 mg/gcr] [estimated glomerular filtration rate 1–3 rangements. Yonekura et al recently identified a novel (eGFR) by the Modification of Diet in Renal Disease Study splice variant of RAGE that would serve as a decoy receptor, (MDRD), 10725 mL/min/1.73m (mean  SD)], n50; and named it endogenous secretory RAGE (esRAGE). es- microalbuminuria (30  ACR 300 mg/gcr) (eGFR, RAGE is secreted from expresser cells exemplified by vas- 10827 mL/min/1.73m ), n11; macroalbuminuria (ACR cular endothelial cells and is able to captures RAGE ligands 300 mg/gcr) (eGFR, 8228 mL/min/1.73m ), n9; renal extracellularly, thereby protecting cells from AGE-induced insufficiency (Cr 2.0 mg/dL) (eGFR, 1416.7 mL/min/ 4 2 injury. Recently, we reported that type 1 diabetic patients 1.73m ), n5. Five patients in http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Arteriosclerosis, Thrombosis, and Vascular Biology Wolters Kluwer Health

Endogenous Secretory Receptor for Advanced Glycation Endproducts Levels Are Correlated With Serum Pentosidine and CML in Patients With Type 1 Diabetes

Loading next page...
 
/lp/wolters-kluwer-health/endogenous-secretory-receptor-for-advanced-glycation-endproducts-kN00Zb4qll
ISSN
1079-5642
eISSN
1524-4636
DOI
10.1161/01.ATV.0000251533.18013.67
pmid
17185626

Abstract

Letter to the Editor Endogenous Secretory Receptor for Advanced Glycation Endproducts Levels Are Correlated With Serum Pentosidine and CML in Patients With Type 1 Diabetes Junnosuke Miura, Yasuhiko Yamamoto, Mari Osawa, Takuo Watanabe, Hideto Yonekura, Yasuko Uchigata, Hiroshi Yamamoto, Yasuhiko Iwamoto dvanced glycation end products (AGEs) and receptor therapy and insulin dose was 0.830.31 U/kgBw. These for AGE (RAGE)-mediated mechanism has been patients included: normoalbuminuria [albumin creatinine ra- Aimplicated in the pathogenesis of the vascular de- tio (ACR) 30 mg/gcr] [estimated glomerular filtration rate 1–3 rangements. Yonekura et al recently identified a novel (eGFR) by the Modification of Diet in Renal Disease Study splice variant of RAGE that would serve as a decoy receptor, (MDRD), 10725 mL/min/1.73m (mean  SD)], n50; and named it endogenous secretory RAGE (esRAGE). es- microalbuminuria (30  ACR 300 mg/gcr) (eGFR, RAGE is secreted from expresser cells exemplified by vas- 10827 mL/min/1.73m ), n11; macroalbuminuria (ACR cular endothelial cells and is able to captures RAGE ligands 300 mg/gcr) (eGFR, 8228 mL/min/1.73m ), n9; renal extracellularly, thereby protecting cells from AGE-induced insufficiency (Cr 2.0 mg/dL) (eGFR, 1416.7 mL/min/ 4 2 injury. Recently, we reported that type 1 diabetic patients 1.73m ), n5. Five patients in

Journal

Arteriosclerosis, Thrombosis, and Vascular BiologyWolters Kluwer Health

Published: Jan 1, 2007

There are no references for this article.